DPP4 and type 2 diabetes mellitus: Among the various glucose-lowering agents used to treat T2D, 2 classes of incretin-based therapies, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP4i), lower postprandial TGs (5, 6).